This site is intended for US audiences only. If you are a resident of the European Union, please click here for the EU version of our site.
Therapeutic Options for PNH
Helping Patients Manage Hemolysis and Achieve a Better Quality of Life
Historically, there have been few options for the treatment of PNH. However, major advances have occurred and options now include monoclonal antibodies, palliative therapies, like transfusions and steroids, and bone marrow transplantation (BMT).
Specific proteins that are normally found attached to cells via GPI anchors are absent from the surface of PNH cells. Monoclonal antibody therapy in PNH interrupts the complement cascade and helps preserve PNH cells, thereby significantly reducing chronic hemolysis (as measured by LDH).1,2
Palliative therapeutic options: transfusions, corticosteroids, anticoagulants, androgen therapy, and supplements such as folic acid and iron.3,4
Bone marrow transplantation (BMT) remains the only curative option for PNH, but is associated with high rates of morbidities and mortality.5-8
Click on the links below to watch Dr Jeff Patten, MD, present videos of short case studies about patients with PNH.
- Patient Misdiagnosed With Myelodysplastic Syndromes
- Patient With Coombs-Negative Hemolytic Anemia
- Patient With Hemoglobinuria
- Patient With Prior Negative Flow Cytometry Presents With Aplastic Anemia
- Patient With Prior Negative Flow Cytometry Presents With Unexplained Thrombosis
- Patient With Unexplained Thrombosis and Aplastic Anemia